no more compound tirzepatide FDA says compounding pharmacies can keep making weight-loss med tirzepatide, for now no more compounding tirzepatide Compounded

PlexusDx supports this personalized context through baseline metabolic assessment and optional genetic insight into peptide pathway predispositions, enabling more precise provider conversations before dose escalation

GLP-1 prescriptions compared to Novos 42%

In UK practice, those are regulatory and patient-safety questions first, and treatment questions second

We assume that Novo Nordisk is capable of growing GLP-1 sales across indications from roughly $24 billion in 2023 to nearly $75 billion by 2031, prior to the patent expiration for semaglutide, the molecule in Ozempic and Wegovy

Itami N, Shirasuna K, Kuwayama T, Iwata H